NHS England Suspends New Hormone Treatment Referrals for 16-17 Year Olds
NHS England has implemented a significant pause on new referrals for gender-affirming hormone treatment specifically for individuals aged 16 and 17. This decisive action follows a comprehensive review that concluded there is insufficient evidence to justify the continued provision of such treatments for this age group.
Immediate Suspension of New Referrals
The therapy, which involves prescribing masculinising or feminising hormones, was previously accessible through the NHS for 16 and 17-year-olds diagnosed with gender dysphoria who met specific clinical criteria. However, as of this week, all new referrals have been formally suspended. This treatment can trigger irreversible physical alterations, including breast development from oestrogen or voice deepening from testosterone.
Cass Review Recommendations and NHS Response
The 2024 Cass Review into children's gender care, led by Baroness Hilary Cass, strongly advocated for "extreme caution" in administering such treatments to young people. The review emphasised the need for a "clear clinical rationale for providing hormones at this stage rather than waiting until an individual reaches 18." In response, NHS England conducted its own evaluation and determined that the available evidence remains too inconclusive to ascertain whether such treatment is beneficial or detrimental to adolescents with gender dysphoria.
Professor James Palmer, national medical director for specialised services at NHS England, stated: "Following the Cass Review, NHS England commissioned an in-depth review of all available clinical evidence for using oestrogen or testosterone either alone or with other medications to treat gender incongruence and dysphoria. This review has established that the available evidence does not support the continued use of masculinising or feminising hormones to treat gender incongruence or dysphoria for young people under 18."
Current Patients and Consultation Process
NHS England has confirmed that 16 and 17-year-old patients currently undergoing cross-sex hormone therapy can continue their treatment, but each case must be individually reviewed with clinicians. Simultaneously, a 90-day public consultation has been launched on proposals for the NHS to cease offering this treatment as a standard procedure. The treatment will remain suspended during this consultation period while NHS England evaluates anticipated thousands of submissions before reaching a final decision.
Broader Context of Youth Gender Care
This development occurs within a broader context of evolving approaches to youth gender care. A clinical trial examining the effects of puberty blockers on children aged 10 and above, which commenced in November, was halted last month before any participants were enrolled due to concerns about "unquantified risk" of "long-term biological harms." The use of such medications to delay or halt puberty was already prohibited for those under 18 in 2024.
Reactions from Advocacy Groups
The decision has sparked strong reactions from various advocacy groups. Tammy Hymas, policy lead at TransActual, stated: "Banning new prescriptions of gender-affirming hormones for 16 and 17-year-olds is a profound attack on young people's bodily autonomy with trans people yet again cruelly singled out by this government."
Conversely, Helen Joyce, director of advocacy at Sex Matters, commented: "This pause comes too late for many children. Under-18s are simply too young to consent to such irreversible, life-changing consequences. This pause now needs to be made permanent, as part of the long road back to sanity on gender issues for the NHS."
Gender Plus, which operates the only CQC Outstanding registered provider of care to transgender people from age 16, expressed dismay at the decision, noting that their practice aligns with international best practice and Endocrine Society guidance that such medication may be introduced in adolescents once persistence of gender incongruence is confirmed and capacity to consent is established, typically by age 16.
NHS England emphasised that specialist support for under-18s managing gender incongruence continues to be available, including mental health support and referral to specialist children and young people's gender services where appropriate.
